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The 5-HT1A receptor and 5-HT
transporter in temporal lobe epilepsy
ABSTRACT
Objective: To study 5-HT transport and 5-HT1A receptors in temporal lobe epilepsy (TLE) and
depression.
Methods: Thirteen patients had PET with [11C]DASB for 5-HTT and [18F]FCWAY for 5-HT1A receptor
binding, MRI, and psychiatric assessment. Sixteen healthy volunteers had [11C]DASB, 19 had [18F]
FCWAY, and 6 had both PET studies. We used a reference tissue model to estimate [11C]DASB
binding. [18F]FCWAY volume of distribution was corrected for plasma-free fraction. Images were nor-
malized to common space. The main outcome was the regional asymmetry index. Positive asymmetry
indicates relative reduced binding (reflecting transporter activity) ipsilateral to epileptic foci.
Results: Mean regional [11C]DASB binding and asymmetry did not differ between patients and
controls. [18F]FCWAY asymmetry was significantly greater for patients than controls in hippo-
campus, amygdala, and fusiform gyrus. On analysis of variance with region as a repeated mea-
sure, depression diagnosis had a significant effect on [11C]DASB asymmetry, with significantly
higher [11C]DASB asymmetry in insular cortex (trend for fusiform gyrus). In insular cortex, patients
had a significant correlation between [18F]FCWAY asymmetry and [11C]DASB asymmetry.
Conclusions: Our study showed increased [11C]DASB asymmetry in insula and fusiform gyrus, and
relatively reduced transporter activity, in subjects with both TLE and depression, as compared to
subjects with TLE alone, implying reduced reuptake and thus increased synaptic 5-HT availability.
This finding may represent a compensatory mechanism for 5-HT1A receptor loss. Altered sero-
tonergic mechanisms have an important role in TLE and concomitant depression. Neurology
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GLOSSARY
5-HTTLPR 5 5-HTT gene-linked polymorphic region; AED5 antiepileptic drug; AI5 asymmetry index; ANOVA5 analysis of
variance; DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders, 4th edition; [18F]FC 5 [18F]fluorocyclohexane-
carboxylic acid; GM 5 gray matter; MDD 5 major depressive disorder; MNI 5 Montreal Neurological Institute; MRTM2 5
2-parameter multilinear reference tissue model; MTS 5 mesial temporal sclerosis; PVC 5 partial volume correction; ROI 5
region of interest; SPM2 5 Statistical Parametric Mapping 2; SSRI 5 selective serotonin reuptake inhibitor; TLE5 temporal
lobe epilepsy; VNTR 5 variable number of tandem repeats.
Serotonin (5-HT) exerts antiseizure effects in experimental models mediated by 5-HT1A recep-
tors, by hyperpolarizing hippocampal CA3 membranes.1 Some antiepileptic drugs (AEDs) may
exert antiseizure effects by blocking 5-HT reuptake.2
PET studies showed reduced 5-HT1A receptor binding ipsilateral to temporal lobe epilepsy
(TLE) foci.3–5 Not due to hippocampal atrophy, reductions are more pronounced in seizure
onset than secondary spread regions.5,6
Epidemiologic and clinical data support relationships between epilepsy and depression, one of
the most common epilepsy comorbidities.7 A history of depression increases risk for later epilepsy
development.8 Otherwise healthy patients with major depressive disorders (MDD) may have
limbic 5-HT1A receptor binding reductions.9–11 5-HT1A receptor PET studies in patients with
both TLE and depression showed additional binding alterations compared to TLE alone.5,7,12,13
From the Clinical Epilepsy Section, National Institutes of Neurological Disorders and Stroke (A.M., A.F., I.D., W.H.T.), PET Department, Clinical
Center (P.H.), and Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health (A.N.), NIH, Bethesda, MD; and
Clinical Neuroimaging Laboratory (D.M.C.), Departments of Anatomy & Psychiatry, National University of Ireland Galway, Galway, Ireland.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
© 2013 American Academy of Neurology 1465
In addition to documented 5-HT receptor
abnormalities, studies in patients with mood
disorders suggested a role for the serotonin
transporter (5-HTT), which modulates 5-HT
reuptake in the synaptic cleft.14–18 Subjects with
1 or 2 copies of the short allele of the 5-HTT
promoter polymorphism had more depressive
symptoms, diagnosable depression, and suici-
dality in relation to stressful life events than
those homozygous for the long allele.19
We used PET in patients and healthy con-
trols to test the hypothesis that 5-HT transporter
is reduced in TLE, with greater reductions in
concomitant depression.
METHODS Subjects. We included 13 patients (9 left focus, 4
right; 7 female; age 34.56 8.4, mean6 SD) referred to the National
Institute of Neurological Disorders and Stroke, Clinical Epilepsy
Section, for uncontrollable seizures (table e-1 on the Neurology®
Web site at www.neurology.org). All had focal seizures, with or
without secondary generalization, as established by ictal video-EEG
monitoring. All patients had a standard 1.5 or 3 T clinical MRI
including T1- and T2-weighted, fluid-attenuated inversion recovery,
and 3D volume sequences. Patients were taking a variety of AEDs;
one had been taking 20 mg/day fluoxetine until 2 months before the
study. We also scanned 29 healthy volunteers (12 female; age 33.7
6 8.5, mean 6 SD) who had never met DSM-IV criteria for a
psychiatric disorder. Healthy volunteers received a general physical
examination and routine laboratory tests. One control subject was
taking Synthroid at a stable dose with thyroid-stimulating hormone
levels within normal limits. No patient or healthy volunteer re-
ported a history of substance abuse. All subjects had to abstain
from smoking and ethanol intake for at least 2 weeks before the
study.
All subjects completed Beck Depression Inventory–II as well
as a Structured Clinical Interview for DSM-IV Axis I Disorders
performed by a trained psychologist. The NIH PET Department pre-
pared the 5-HTT ligand [11C]-3-amino-4-(2-dimethylaminomethyl-
phenylsulfanyl)-benzonitrile ([11C]DASB) and the 5-HT1A ligand
18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl) piperazin-1-yl]
ethyl-N-(2-pyridyl) cyclohexane carboxamide ([18F]FCWAY).
All patients completed a structural MRI and [11C]DASB and
[18F]FCWAY PET scans. All control subjects completed a structural
MRI. Sixteen of the 29 control subjects completed [11C]DASB,
19 [18F]FCWAY PET, and 6 both the [11C]DASB and the
[18F]FCWAY PET scans.
Standard protocol approvals, registrations, and patient
consents. The NIH Combined Neurosciences Institutional Review
Board and the Radiation Safety Committee approved the protocol.
We obtained informed consent from all protocol participants.
Data acquisition and processing. T1-weighted MRI were
acquired on a GE 1.5 or 3 T scanner using a 3D spoiled gradient-
recalled acquisition or magnetization-prepared rapid acquisition with
gradient echo (voxel size: 0.9375 3 0.9375 3 1.5 mm).
PET images were acquired on a GE Advance scanner in 3D
mode with a reconstructed 3D spatial resolution 5 6 mm full-
width at half maximum, scanning 35 simultaneous slices with
4.25-mm slice separation. [11C]DASB was synthesized as previ-
ously described.20 After IV bolus administration of [11C]DASB
(patients 18.5 6 3.3, volunteers 18.7 6 2.8 mCi) a 120-minute
dynamic emission scan was acquired as 33 frames of increasing length
(number3 frame duration in minutes: 63 0.5; 33 1; 23 2; 223
5). We corrected for head motion by aligning later frames of longer
duration (11 to 33) to a mean image of all frames using Statistical
ParametricMapping 2 (SPM2) software (www.fil.ion.ucl.ac.uk/spm)21
and MEDx (Sensor Systems, Sterling, VA). The motion-corrected
PET image was coregistered to the corresponding subject’s structural
MRI using the Oxford Centre for FunctionalMRI of the Brain Linear
Imaging Registration Tool (FLIRT) using a mutual information cost
function.22
[11C]DASB images were processed and analyzed as previously
described.15 Briefly, we used a 2-parameter multilinear reference tis-
sue model (MRTM2)23 to estimate voxel-wise 5-HTT binding
parameters. The MRTM2 allows voxel-wise estimation of the non-
displaceable receptor binding parameter BPND by using a receptor-
free reference region, in this case the cerebellum, to estimate binding
kinetics without using arterial data. The estimation is computation-
ally less intensive and nearly identical to nonlinear one-tissue
kinetic analysis, which requires arterial sampling. We generated
parametric images of tracer delivery (R1) and binding from the
dynamic [11C]DASB PET data using MRTM2 as described previ-
ously23,24 in PMOD 2.5 (PMOD Technologies, Ltd., Zurich,
Switzerland). [18F]FCWAY was synthesized as previously described.6
After an IV bolus injection of 10 mCi of [18F]FCWAY over 10
seconds, a series of dynamic frames (1 to 5 minutes) was acquired
for 120 minutes. Thirty radial arterial blood samples were taken to
quantify [18F]FCWAY concentration and the metabolite [18F]fluo-
rocyclohexanecarboxylic acid ([18F]FC) measured.6 Brain tissue activ-
ity frames were corrected for brain acid metabolite [18F]FC, vascular
radioactivity, and F-18, fluoride metabolite spillover into the skull.
An MRI-based partial volume correction (PVC) was applied.6
Patients were monitored clinically by an epilepsy nurse prac-
titioner for ictal activity during scans. None reported experiencing
seizures for at least 2 days before PET scans. All except one
patient had the 2 scans no more than 2 days apart. In one case
they were separated by 5 months as the FCWAY had to be re-
scheduled due to technical difficulties.
Data analysis. To transform separate [18F]FCWAY and [11C]DASB
binding images into a single stereotactic space for comparison, each
MRI was spatially normalized to a common stereotactic array, the
Montreal Neurological Institute (MNI) template, and that trans-
form applied to the PET images; all images were resampled into 23
23 2 mm voxels using SPM2. Masks expressing the proportion of
gray matter (GM) for each voxel were extracted from each MRI
using SPM2 (GM mask factor 0.3).
Regions of interest (ROI) were drawnmanually on a mean image
of control subjects’ MRI that had been normalized to MNI space.
Template ROIs included the insula, hippocampus, amygdala, para-
hippocampal gyrus, fusiform gyrus, and cingulate cortex (figure e-1).
Spatially normalized [18F]FCWAY and [11C]DASB PET images were
multiplied by GM masks generated from respective MRI images.
Template ROIs were applied to each subject’s PET 3 GM image
and mean voxel values were extracted for each ROI. [18F]FCWAY
volume of distribution (VT) was corrected for tracer plasma-free frac-
tion.25 For subsequent analysis, images of patients with right hemi-
sphere foci were reversed to make the left side ipsilateral to the seizure
focus. The main outcome measure was the asymmetry index [AI 5
2 3 (right VT – left VT)/(right VT 1 left VT)] calculated for each
region. A positive asymmetry indicates relative reduced binding ipsi-
lateral to the epileptic focus.
Statistical analysis. We used Student t tests to compare
regional binding values ipsilateral and contralateral to the
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epileptic focus (for controls, left-sided regions were arbitrarily
considered ipsilateral for calculation of asymmetry). For patients,
single linear regression models were used to assess the effect of age
at epilepsy onset and epilepsy duration on [11C]DASB BPND and
[18F]FCWAY V/f1 as well as the relation between [11C]DASB
and [18F]FCWAY asymmetry in selected regions. We used anal-
ysis of variance (ANOVA) with region as a repeated measure to
assess the effects of sex, MDD diagnosis, and the presence of
mesial temporal sclerosis (MTS). We only included main effects
in our model. Analyses were performed in SPSS version 19 (IBM
Inc., Armonk, NY). All reported significance values are 2-tailed.
Using the Dunn-Sidak correction for multiple comparisons, sig-
nificance was set at p 5 0.01.26
RESULTS All patients completed both [18F]FCWAY
and [11C]DASB PET. Thirteen male and 6 female con-
trols (mean age 34.7 6 8.5) completed [18F]FCWAY,
and 9 male and 7 female controls (mean age 31.3 6
8.2) completed [11C]DASB PET. The difference in the
sex distributions between patients and controls for each
scan was not significant.
Four patients had a history of MDD diagnosed on
the Structured Clinical Interview for DSM-IV.7 Two
of these reported depressive symptoms at the time of
the scan. Three of the 4 had a right temporal focus
and 1 a left temporal focus.
Sex did not affect [11C]DASB binding or
[18F]FCWAY binding in either patients or controls.
Mean regional [11C]DASB binding and asymmetry did
not differ between patients and controls (table 1). Mean
[18F]FCWAY binding was decreased in ipsilateral hip-
pocampus (t5 4.4, p, 0.001) and amygdala (t5 4.9,
p , 0.001), compared to contralateral regions. There
were no side to side differences in [11C]DASB binding.
[18F]FCWAY asymmetry was greater for patients than
controls in hippocampus (p , 0.01), amygdala (p 5
0.01), and fusiform gyrus (p 5 0.001) (table 2).
On ANOVA with region as a repeated measure,
MDD diagnosis had a significant effect on [11C]DASB
AI (F 5 9.3, p , 0.01). Post hoc analysis showed
patients with a history of depression had higher
[11C]DASB asymmetry in insular cortex (t 5 4.3,
p , 0.004) with a trend for fusiform gyrus (p ,
0.05) (table 3 and figure 1). Adding side of seizure focus
to the model did not affect the results (F 5 0.397 for
focus side; F 5 1.69 for interaction with history of
depression). There was a trend (0.05 , p , 0.10) for
higher Beck Depression Inventory score to be correlated
with increased insular [11C]DASB asymmetry.
Age at epilepsy onset, epilepsy duration, side of
focus, the presence of MTS, or lamotrigine, carbamaz-
epine, or oxcarbazepine did not have significant effects
on [11C]DASB binding in patients with TLE. We did
not find any significant effects for depression history
or MTS on [18F]FCWAY asymmetry.
In insular cortex, there was a correlation between
[18F]FCWAY AI and [11C]DASB asymmetry for
patients (R2 5 0.52; F 5 12.0; p 5 0.005) but not
controls, suggesting that greater loss of 5-HT1A
receptors may lead to reduced transport as a compen-
satory mechanism (figure 2). A trend was present for
controls (R2 5 0.39; F 5 2.5).
DISCUSSION Our study provides additional evidence
for involvement of serotonin in epilepsy and its associa-
tion with depression, supporting results from previous
clinical and imaging studies. We found an increase in
[11C]DASB asymmetry in insula and fusiform gyrus,
and thus relatively reduced transporter activity, in sub-
jects with both TLE and depression, as compared to
subjects with TLE alone, implying reduced reuptake
and thus increased synaptic 5-HT availability. This find-
ing may represent a compensatory mechanism for
reduced 5-HT receptor binding. We found the stron-
gest effect for depression on [11C]DASB binding in the
insula, with lesser effects in mesial temporal regions. In
patients with MDD, some studies have shown
reduced17,18 and others increased [11C]DASB bind-
ing.15,16 Both MDD and TLE may be more heteroge-
neous than understood currently.
Patients with TLE and depression studied with
PET using the highly selective 5-HT1A receptor ligands
[18F]FCWAY and [11C]WAY had greater 5-HT1A
receptor binding reductions than those with TLE
alone.5,7,12 One study using another 5-HT1A ligand,
[18F]MPPF, found patients with TLE and depression
had relatively increased binding in some regions com-
pared to patients with epilepsy alone.13 These dichoto-
mous findings may be due to differences in receptor
affinity between the 2 tracers. [18F]MPPF is more sen-
sitive to synaptic 5-HT levels than [18F]FCWAY,
potentially leading to relatively increased exogenous
radioligand binding when endogenous serotonin avail-
ability is reduced.13
Using the PET ligands [11C](1)McN5652 and
[11C]DASB, elevations in 5-HTT availability were found
in subjects withMDD and bipolar disorder compared to
controls in structures including thalamus, insula, pre-
frontal and cingulate cortex.14–16 Other investigators re-
ported decreased 5-HTT availability in midbrain,
Table 1 [11C]DASB asymmetry indices in
patients and controlsa
Region Controls Patients
Insula 212.2 6 9.0 26.6 6 15.8
Hippocampus 25.0 6 12.1 21.6 6 9.7
Amygdala 22.3 6 7.9 1.6 6 11.3
Parahippocampal gyrus 26.8 6 12.3 20.5 6 18.6
Fusiform gyrus 29.1 6 21.2 0.02 6 18.8
Cingulate gyrus 23.3 6 15.1 23.3 6 22.5
aNo differences were significant.
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amygdala, hippocampus, thalamus, putamen, and ante-
rior cingulate cortex.17,18
We did not find any effects of TLE itself on
[11C]DASB binding. However, our study was too small
to rule out a relationship, or assess any potential clinical
application of [11C]DASB PET. Several previous studies
have suggested a potential role for 5-HTT in epilepsy.
An association analysis found that patients with TLE
had a higher frequency of the 10 repeat for the 44-bp
insertion/deletion polymorphism in the 59 regulatory
region of the 5-HTT promoter second intron compared
with controls.27 A study combining analysis of the
5-HTT gene-linked polymorphic region (5-HTTLPR)
biallelic and 5-HTT-variable number of tandem repeats
(VNTR) allele variants found that neither alone differed
between patients and controls, but a combination of
low-efficiency genotypes was more common in pa-
tients.28 Homozygous carriers for the 12-repeat VNTR
allele had higher risk for mesial TLE with hippocampal
sclerosis not responding to AEDs compared to carriers
of the 10-repeat VNTR allele.29 A similar study also
found that patients with TLE with the combination
of more efficient genotypes (5-HTTLPR L/L and
VNTR-212/12) had worse response to AEDs.30 Thus,
some studies suggest high (leading to increased reuptake
and reduced synaptic 5-HT) and others low 5-HTT
expression (implying decreased reuptake and thus
increased synaptic 5-HT) could be related to TLE itself,
and that higher 5-HTT activity, and presumably lower
synaptic 5-HT availability, could be related to poor
AED response. One study showed no relation between
5-HTT variants and TLE.31 Preclinical data suggest that
selective serotonin reuptake inhibitors (SSRIs) may be
most active in partial seizure models, although not all the
effects may be related to 5-HT directly.32 Limited clin-
ical data suggesting that SSRIs may have antiseizure
effects also support a role for 5-HT in seizure suscepti-
bility.2,33 However, the wide variety of 5-HT receptors
and their varying physiologic effects complicates inter-
pretation of study results.2
Our study has some limitations. The analysis in
SPM2 degraded native 3D image resolution from 6
mm to 8 mm. Although we found an effect of
MDD history on [11C]DASB asymmetry, the small
number of subjects in our study suggests cautious
interpretation. Our sample size was too small to assess
effects of seizure frequency, and might account for
failure to find effects of epilepsy duration or onset
age. The small sample size may also account for fail-
ure to find an effect of depression on [18F]FCWAY
binding. Only 6 subjects completed both PET scans,
making it more difficult to compare the relation of
[11C]DASB and [18F]FCWAY binding asymmetry
between patients and control groups. Our results will
need to be confirmed by additional studies.
Although 3 of 4 patients with a history of depres-
sion had a right temporal and 1 a left temporal focus,
the side of focus did not affect our results. Studies of
Table 2 [18F]FCWAY asymmetry indices in patients and controls
Region Controls Patients
Significance
(uncorrected)
Insula 24.4 6 6.7 0.83 6 9.5 NS
Hippocampus 9.0 6 14.5 32.8 6 25.2 0.007
Amygdala 3.4 6 17.6 25.4 6 17.2 0.001
Parahippocampal gyrus 20.13 6 18.1 12.1 6 15.7 ,0.06
Fusiform gyrus 27.39 6 10.2 13.2 6 17.2 0.001
Cingulate gyrus 20.68 6 21.9 8.4 6 19.6 NS
Abbreviation: NS 5 not significant.
Table 3 [11C]DASB asymmetry index in patients with and without major depressive disorder
Region Patients without depression Patients with depression Significance (uncorrected)
Insula 214.6 6 10.3 11.5 6 9.6 0.001
Hippocampus 21.1 6 10.8 22.6 6 8.0 NS
Amygdala 4.6 6 6.8 25.0 6 17.3 NS
Parahippocampal gyrus 24.9 6 14.3 9.4 6 25.4 NS
Fusiform gyrus 26.6 6 17.8 15.0 6 11.8 0.05
Cingulate gyrus 25.1 6 25.7 0.62 6 15.5 NS
Abbreviation: NS 5 not significant.
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the effect of the side and location of epileptic foci, as
well as the presence or absence of MRI lesions includ-
ing hippocampal sclerosis, have not found consistent
results.34
None of the patients was currently taking antide-
pressants, but all were on AEDs, and one had a history
of past SSRI therapy. Studies in MDD have suggested
that past SSRI exposure might affect 5-HT1A receptor
binding even when patients are not on the drugs;
patients who had never received antidepressants had
higher 5-HT1A receptor binding than either healthy
controls or nonmedicated patients with past expo-
sure.10 There are no data on the effect of AEDs on
5-HTT binding. Carbamazepine and lamotrigine
might affect 5-HT reuptake.2 However, in a previous
study, after correction for free fraction, we found no
significant effects of individual AEDs on 5-HT1A
receptor binding measured with [18F]FCWAY, or dif-
ferences in binding between patients taking AEDs and
healthy volunteers in regions outside the epileptic
focus.25 We did not find any AED effects in the pre-
sent study.
We chose to use regions drawn on averaged
healthy subject brains, rather than on individual sub-
ject images, to reduce data variability and operator
bias. Although this approach might have had the
effect of producing apparent greater binding in
healthy subjects, our use of individual subject GM
masks would have corrected for this potential con-
founder. The FCWAY data were processed with an
initial additional PVC, while the DASB data had only
the SPM2 GM mask applied. The initial PVC is
important for FCWAY due to the potential for
spill-in and spill-out from the fluoridated metabolite.6
Figure 1 [11C]DASB PET
(A) [11C]DASB PET in a patient with no history of depression shows symmetrical insula binding. (B) [11C]DASB PET in a
patient with a history of depression shows relatively reduced right insula binding.
Figure 2 Relation of [11C]DASB asymmetry index to [18F]FCWAY asymmetry
index in patients
R2 5 0.522. AI 5 asymmetry index.
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For [18F]FCWAY, we chose to use Vt/f1 rather
than BP_F, in order to avoid the possible errors that
could be introduced by using the cerebellum as a
measure of nonspecific binding. Since nonspecific
binding is very low, this measure is equivalent to
Vs/f1, and BP_F.35,36 However, since AI was our
main outcome measure, the choice of binding param-
eter would not affect the results.
Depression has a severe effect on quality of life in
people with epilepsy.37 It may be associated with poor
AED response and outcome after temporal lobec-
tomy.38,39Moreover, postictal 5-HT neuronal dysfunc-
tion may be associated with respiratory depression, and
potentially sudden unexpected death in epilepsy, both
in patients and in DBA/2 mice, where postictal respi-
ratory arrest is reduced by SSRI pretreatment.40 Our
results support data from previous imaging, pharma-
cologic, and clinical studies suggesting that altered
serotonergic transmission may play an important role
in TLE and its comorbidities.
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